Vaccinex Company Overview
About Vaccinex
Vaccinex (NASDAQ:VCNX) is a biotechnology company focused on the discovery and development of targeted biotherapeutics to treat serious diseases and conditions including cancer, neurodegenerative diseases, and autoimmune disorders. Leveraging its proprietary ActivMAb® platform, Vaccinex has been at the forefront of creating antibody therapies that can potentially transform patient care in these challenging areas. The company's flagship projects include pioneering treatments for Huntington’s disease and non-small cell lung cancer, with the objective of advancing these therapies through clinical trials to bring new hope to patients. At its core, Vaccinex is dedicated to harnessing the power of the immune system to fight disease and improve lives.
Snapshot
Operations
Products and/or services of Vaccinex
- Pepinemab, a monoclonal antibody targeting Semaphorin 4D for cancer and neurodegenerative diseases.
- Signal transduction modulation platform, developing therapies by modulating signaling pathways for various diseases.
- Antibody Discovery Platform, leveraging technology to discover novel antibodies for therapeutics and diagnostics.
- Neurological disease research, focusing on identifying biomarkers and targets for treatments in diseases like Huntington's.
- Cancer immunotherapy projects, aiming to develop treatments that stimulate the immune system to fight cancer.
Vaccinex executive team
- Dr. Maurice Zauderer Ph.D.Co-Founder, CEO, President & Director
- Dr. Elizabeth E. Evans Ph.D.COO and Senior VP of Discovery & Translational Medicine
- Dr. Ernest S. Smith Ph.D.Senior VP of Research & Chief Scientific Officer
- Ms. Jill Sanchez CPAChief Financial Officer
- Dr. John E. Leonard Ph.D.Senior Vice President of Development